Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2023-07-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
自愿披露关于西达本胺联合R-CHOP治疗弥漫大B细胞淋巴瘤适应症拟纳入优先审评程序的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Microchip Biotech Co., Ltd. regarding the voluntary disclosure of a drug (Chidamide combined with R-CHOP) being included in a priority review program by the National Medical Products Administration. It details the drug's basic information, approved indications, clinical trial results, and risk warnings. The document is relatively short (2165 characters) and serves as a regulatory announcement about a drug approval process and related risks. It does not contain financial statements, management discussion, or detailed financial data. It is not an annual or interim report, earnings release, or any form of financial filing. It is also not a meeting material, voting result, or insider transaction. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about drug approval status and risk disclosure, which does not fit other specific categories.
2023-07-20 Chinese
自愿披露关于西达本胺联合R-CHOP治疗弥漫大B细胞淋巴瘤上市申请获受理的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acceptance of a new drug marketing application by the National Medical Products Administration (NMPA) in China. It details the drug's clinical trial status, regulatory acceptance, and risk warnings to investors. The document is relatively short (1595 characters) and serves as a regulatory update or announcement rather than a detailed financial report or presentation. It does not contain financial statements, management discussion, or detailed financial data. It is not an earnings release, annual report, or any form of financial filing. It is also not a voting result, board change, or capital update. The content fits best under a general regulatory announcement category, which is the Regulatory Filings (RNS) classification in the provided taxonomy.
2023-07-18 Chinese
关于转股结果暨股份变动的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the results of convertible bond conversions and related share capital changes for Shenzhen Microchip Biotechnology Co., Ltd. It details the amount of convertible bonds converted into shares during a specific quarter and cumulatively, as well as the remaining unconverted bonds. It also provides information on share capital changes due to these conversions. The document references regulatory approvals and provides contact information for investor inquiries. The content is focused on capital structure changes due to convertible bond conversions rather than a full financial report or earnings release. The document length is under 5,000 characters and is a formal announcement of share capital changes related to convertible bonds. Therefore, the most appropriate classification is "Share Issue/Capital Change (SHA)".
2023-07-03 Chinese
关于“微芯转债”2023年付息的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the interest payment for its convertible bonds "Microchip Convertible Bonds" for the year 2023. It details the bond issuance, interest calculation, payment dates, tax information, and contact details. The document is relatively short (3404 characters) and focuses on the announcement of the bond interest payment event rather than providing a full financial report or detailed financial statements. It does not contain comprehensive financial data or analysis typical of an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is not a regulatory certification or officer attestation. The content fits best with a Capital/Financing Update (CAP) as it relates to bond issuance and interest payment information. Therefore, the appropriate classification is CAP with high confidence.
2023-06-28 Chinese
自愿披露关于CS23546片临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the approval of a clinical trial application for a drug (CS23546). It includes details about the approval notice from the National Medical Products Administration, product information, and risk warnings. The document is short (1102 characters) and is an announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it is not about publishing a report but about disclosing regulatory approval. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-06-26 Chinese
2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2023 first extraordinary general meeting of shareholders of Shenzhen Microchip Biotechnology Co., Ltd. It includes details about the meeting date, attendance, voting results, and legal witness statements. The content focuses on the voting outcomes and procedural compliance rather than presenting a full report or financial statements. The document length is short (1439 characters), and it serves as an official announcement of voting results from a shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-06-26 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.